697 Tumor-targeted CD28 costimulatory bispecific antibodies enhance T cell activation in solid tumors

697 Tumor-targeted CD28 costimulatory bispecific antibodies enhance T cell activation in solid tumors

Bibliographic Details
Main Authors:	Gregory Moore, Michael Hedvat, Christine Bonzon, Rumana Rashid, Umesh Muchhal, John Desjarlais, Irene Leung, Veronica Zeng, Juan Diaz, Kendra Avery, Norm Bartlow, Charles Bakhit, Matthew Dragovich, Liz Bogart
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2020-11-01
Series:	Journal for ImmunoTherapy of Cancer

Similar Items

698 PD-L1 targeted CD28 costimulatory bispecific antibodies enhance T cell activation in solid tumors
by: Jing Qi, et al.
Published: (2021-11-01)

Bispecific costimulatory molecules for activation of tumor-killing lymphocytes
by: Wels W, et al.
Published: (2004-07-01)

564 Potency-reduced and extended half-life IL12 heterodimeric Fc-fusions exhibit strong anti-tumor activity with potentially improved therapeutic index compared to native IL12 agents
by: Ke Liu, et al.
Published: (2020-11-01)

1060 Optimally engineered IL18 Fc-fusion proteins balance potency and pharmacokinetics to promote strong anti-tumor activity
by: Christine Bonzon, et al.
Published: (2023-11-01)

CD28 costimulatory signal induces protein arginine methylation in T cells.
by: Blanchet, F, et al.
Published: (2005)

Reoperação em valvopatias: análise de 697 pacientes Reoperations for valvopathies: analyzis of 697 patients
by: Carlos Alberto Mussel Barrozo, et al.
Published: (1994-06-01)

Mouse glucocorticoid-induced tumor necrosis factor receptor ligand is costimulatory for T cells.
by: Tone, M, et al.
Published: (2003)

Recent advances of bispecific antibodies in solid tumors
by: Shengnan Yu, et al.
Published: (2017-09-01)

1174 Costimulatory IgM T-cell engagers with enhanced and durable cytotoxicity
by: Yue Wang, et al.
Published: (2023-11-01)

Co-administration of Lactobacillus gasseri KBL697 and tumor necrosis factor-alpha inhibitor infliximab improves colitis in mice
by: Dae Hee Han, et al.
Published: (2022-06-01)

The development of bispecific antibodies and their applications in tumor immune escape
by: Xiaolong Zhang, et al.
Published: (2017-05-01)

625 Bispecific personalized aptamer for the treatment of solid tumors
by: Erez Lavi, et al.
Published: (2020-11-01)

Molecular modifiers of T cell antigen receptor triggering threshold: the mechanism of CD28 costimulatory receptor.
by: Acuto, O, et al.
Published: (2003)

Evidence implicating the Ras pathway in multiple CD28 costimulatory functions in CD4+ T cells.
by: Sujit V Janardhan, et al.
Published: (2011-01-01)

Signaling via a CD28/CD40 chimeric costimulatory antigen receptor (CoStAR™), targeting folate receptor alpha, enhances T cell activity and augments tumor reactivity of tumor infiltrating lymphocytes
by: Milena Kalaitsidou, et al.
Published: (2023-11-01)

The homodimer interfaces of costimulatory receptors B7 and CD28 control their engagement and pro-inflammatory signaling
by: Andrey Popugailo, et al.
Published: (2023-06-01)

Bispecific Antibodies: A Novel Approach for the Treatment of Solid Tumors
by: Luigi Liguori, et al.
Published: (2022-11-01)

Consideration on the Research and Development of Anti-tumor Bispecific Antibody Drugs
by: Yuanyuan SONG, et al.
Published: (2022-09-01)

Costimulatory blockade of the CD28 / CD80-86 / CTLA-4 balance in transplantation: impact on memory T cells?
by: Simon eVille, et al.
Published: (2015-08-01)

33 Development of a clinical ex vivo assay for the assessment of therapeutic CD28 costimulatory pathway engagement
by: Jing Yang, et al.
Published: (2021-11-01)

Staphylococcal and Streptococcal Superantigens Trigger B7/CD28 Costimulatory Receptor Engagement to Hyperinduce Inflammatory Cytokines
by: Andrey Popugailo, et al.
Published: (2019-04-01)

Universal bispecific antibody for targeting tumor cells for destruction by cytotoxic T cells.
by: Gilliland, L, et al.
Published: (1988)

Overcoming Challenges for CD3-Bispecific Antibody Therapy in Solid Tumors
by: Jim Middelburg, et al.
Published: (2021-01-01)

Radiosynthesis and Preclinical Evaluation of Bispecific PSMA/FAP Heterodimers for Tumor Imaging
by: Kongzhen Hu, et al.
Published: (2022-03-01)

Bispecific T-Cell Engagers Therapies in Solid Tumors: Focusing on Prostate Cancer
by: Diana C. Simão, et al.
Published: (2023-02-01)

Engineering of dendritic cell bispecific extracellular vesicles for tumor-targeting immunotherapy
by: Fang Xu, et al.
Published: (2023-10-01)

Dual Targeting of Tumor Cells with Bispecific Single-Chain Fv-Immunoliposomes
by: Katharina Mack, et al.
Published: (2012-07-01)

L59S F697 (30-39) [fotograf udara]

L71S F697 (203-218) [fotograf udara]

L71S F697 (203-218) [fotograf udara]
by: Malaysia. Direktorat Pemetaan Negara
Published: (1986)

LICOS, a primordial costimulatory ligand?
by: Brodie, D, et al.
Published: (2000)

The interaction properties of costimulatory molecules revisited.
by: Collins, A, et al.
Published: (2002)

Neuroimmune semaphorins as costimulatory molecules and beyond
by: Svetlana P. Chapoval
Published: (2018-04-01)

Targeting Costimulatory Pathways in Systemic Sclerosis
by: Gonçalo Boleto, et al.
Published: (2018-12-01)

103 Inclusion of a Dap10 costimulatory domain enhances anti-tumor efficacy of chimeric PD1-expressing T cells in multiple types of solid tumors
by: Amorette Barber
Published: (2020-11-01)

Specific transcriptional programs differentiate ICOS from CD28 costimulatory signaling in human Naïve CD4+ T cells
by: Casimiro Luca Gigliotti, et al.
Published: (2022-09-01)

Mechanistically modeling peripheral cytokine dynamics following bispecific dosing in solid tumors
by: Jared Weddell
Published: (2023-11-01)

Bispecific BCMA-CD3 Antibodies Block Multiple Myeloma Tumor Growth
by: Lijun Wu, et al.
Published: (2022-05-01)

L61N F697 (41-55) [fotograf udara]

L73N F697 (220-230) [fotograf udara]